Arcus Biosciences, Inc. / Fundamentals
Income statement
- Net revenue
€224.80M - Cost of goods sold
€0.00 - Gross profit
€222.22M - SG&A expenses
€98.67M - R&D expenses
€416.13M - EBITDA
-€253.11M - D&A
€8.58M - EBIT
-€290.00M - Interest expenses
€5.15M - EBT
-€262.55M - Tax expenses
€858.00K - Net income
-€262.55M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€129.56M - Changes in working capital
€28.31M - Operating cash flow
-€290.86M - Capex
€2.57M - Other investing cash flow
€0.00 - Net investing cash flow
€163.88M - Total cash dividends paid
€0.00 - Issuance of common stock
€119.26M - Debt repayment
€0.00 - Other financing cash flow
€84.08M - Net financing cash flow
€205.92M - Foreign exchange effects
€0.00 - Net change in cash
€78.94M - Cash at end of period
€215.36M - Free cash flow
-€288.29M
Balance sheet
- Cash and cash equivalents
€212.78M - Cash and short-term investments
€781.64M - Total receivables
€17.16M - Inventory
€0.00 - Other current assets
€12.87M - Total current assets
€811.67M - Property, plant & equipment
€37.75M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€13.73M - Other non-current assets
€59.20M - Total non-current assets
€110.68M - Total assets
€922.35M - Accounts payable
€24.88M - Short-term debt
€10.30M - Other current liabilities
€84.08M - Total current liabilities
€180.18M - Long-term debt
€83.23M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€136.42M - Total non-current liabilities
€271.13M - Total liabilities
€451.31M - Common stock
€1.54B - Retained earnings
-€1.07B - Other equity
€0.00 - Total equity
€471.04M - Total liabilities and shareholders' equity
€922.35M
Company information
- Market capitalization
€718.00M - Employees
627 - Enterprise Value
€808.26M
Company ratios
- Gross margin
-
98.9% Much better than peer group: -18,753.8% - EBITDA margin
-
-112.6% Much better than peer group: -40,318.3% - EBIT margin
-
-129.0% Much better than peer group: -40,908.6% - EBT margin
-
-116.8% Much better than peer group: -41,309.7% - Net margin
-
-116.8% Much better than peer group: -40,809.8% - ROE
-
-55.7% Much better than peer group: -6,548.3% - ROA
-
-28.5% Much better than peer group: -75.9% - Asset turnover
-
24.4% Better than peer group: 7.4% - FCF margin
-
-130.5% Much better than peer group: -36,468.9% - FCF yield
-40.9% - Efficiency ratio
212.6% - Net sales per employee
-
€358.53K - Net income per employee
-
-€418.74K